Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey
OtoM is a care-gap for Veterans with cancer, despite its perceived value to VA oncology providers. Cisplatin and carboplatin frequently add hearing loss and tinnitus to survivors' treatment burdens. This study offers insights into oncology providers' views on OtoM, guiding efforts to address the identified care gap.
Authors
- James Riley Debacker (ORCID: https://orcid.org/0000-0002-8217-9598)
- Michelle Hungerford
- Trisha Milnes
- Rosemarie Mannino
- Khaya D. Clark (ORCID: https://orcid.org/0000-0002-9537-0754)
- Julie N. Graff (ORCID: https://orcid.org/0000-0002-5708-2794)
- Hunter R. Stuehm (ORCID: https://orcid.org/0000-0002-7301-1427)
- Dawn Konrad‐Martin (ORCID: https://orcid.org/0000-0001-8100-2240)
- Kirsten Johansson
- Cecilia Lacey (ORCID: https://orcid.org/0000-0002-4290-5612)
Institutions
- Oregon Health & Science University (US)
- Portland VA Medical Center (US)
- University Health Care System (US)
- Geriatric Research Education and Clinical Center (US)
- VA Pittsburgh Healthcare System (US)
- VA Portland Health Care System (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cam4.71566
- Primary Topic
- Hearing, Cochlea, Tinnitus, Genetics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health
- Geriatric Research Education and Clinical Center
- National Institute on Deafness and Other Communication Disorders
- NIH Clinical Center